Research, news and information on the effectiveness of oral pre-exposure prophylaxis (PrEP) and its impact on HIV epidemics, as well as clinical issues for PrEP users.

PrEP science: latest news

PrEP science features

PrEP science news from aidsmap

More news

PrEP science news selected from other sources

  • On-Demand PrEP With TDF/FTC Not Associated With Clinically Relevant Decline in Kidney Function

    On-demand pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) is not associated with a significant relevant in kidney function, especially among young people with low pill use and high baseline estimated glomerular filtration rate, investigators in France found.

    10 hours ago | Contagion Live
  • Jean-Michel Molina, MD, on Biomedical Failures of PrEP: Rare, But Serious

    "There are multiple reasons for PrEP failures and they could be at any point in the PrEP continuum of care. From people who may not use their pills as recommended, to a health care system that is not able to provide access to PrEP for people in need, it could be also the physicians who are not ready to prescribe PrEP or not aware that they could use PrEP for preventing HIV in high-risk patients. It could be also the test that we use sometimes that are not able to detect acute HIV infection. And, if you start PrEP in someone with acute HIV infection you will see more resistance."

    14 March 2019 | Contagion Live
  • Gilead's Descovy snared its PrEP data, but can it stand up to Truvada generics?

    Gilead Sciences has the data it’ll need to start transitioning patients taking Truvada for PrEP over to Descovy, a drug with a longer patient life. But once Truvada generics hit, it might be a different story.

    14 March 2019 | FiercePharma
  • Effective HIV Interventions Have Changed the Approach to Trials

    In the past, individuals who were at high risk for HIV infection and who were enrolled in placebo-controlled prevention trials had been typically randomly assigned to either an experimental agent or placebo. However, that trial design—and the way those trials were interpreted—has shifted. This was the topic of discussion during David Dunn’s session yesterday at the Conference on Retroviruses and Opportunistic Infections (CROI) 2019. Dunn is a researcher at University College London in the United Kingdom.

    11 March 2019 | Infectious Diseases Consultant
  • Correlation between HIV, rectal gonorrhea could help PrEP trial designs

    Rectal gonorrhea incidence may serve to estimate what HIV incidence would have been had trial participants not received PrEP, according to study findings.

    12 February 2019 | Healio
  • Can PrEP on Demand for HIV Prevention Work in the U.S.? Experts Answer Your Questions

    The efficacy of on-demand PrEP is uncontroversial, but work is still needed to inform clinicians, PrEP programs, and other HIV programs serving communities of color in the U.S. This was the central theme of a panel discussion about on-demand PrEP at the recent December 3-4 Biomedical HIV Prevention Summit, held December 3 and 4 in Los Angeles.

    17 December 2018 | The Body Pro
  • No new infections during research on preventive HIV pill in Belgium

    According to the latest figures from Sciensano, 890 new diagnoses were made in Belgium last year, mainly in gay men and people from sub-Saharan Africa. This is a decrease of 27% compared to the peak of 2012.

    27 November 2018 | Institute of Tropical Medicine
  • HIV Seroconversion Despite PrEP Therapy

    The tragedy of continued HIV transmission in the era of pre-exposure prophylaxis (PrEP) is explored in detail in a viewpoint article published in Clinical Infectious Diseases.1 The study evaluated a cohort of 14 young black men who have sex with men (MSM) in Atlanta, Georgia, who experienced HIV seroconversion despite administration of PrEP as part of the EleMENt Study.

    22 November 2018 | Infectious Disease Advisor
  • Trying to prevent and diagnose HIV at the same time – a Catch-22?

    The doctors were puzzled by the fact that it wasn’t quite HIV. If it became HIV they could treat it. If it didn’t become HIV and went away they could discharge him. But this just being short of HIV all the time confused them.

    11 November 2018 | Daily Maverick
  • How to evaluate PrEP and vaccines: urgency for next generation compounds

    Several presentations at R4P 2018 looked at the new challenges of evaluating efficacy of new PrEP and vaccine candidates.

    05 November 2018 | HIV i-Base
More news
Tell us why you visited aidsmap today

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?


Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.